Halozyme Therapeutics (HALO +14%) gets a boost from an upgrade to Outperfrom at BMO Capital. The...

|About: Halozyme Therapeutics, Inc. (HALO)|By:, SA News Editor

Halozyme Therapeutics (HALO +14%) gets a boost from an upgrade to Outperfrom at BMO Capital. The firm says meetings with management leave it increasingly confident in its pipeline, particularly the potential for a positive opinion for Herceptin SC in Q113. In addition, its recent collaboration with Pfizer (PFE +1%) will provide additional value drivers over the next 12 months.